Literature DB >> 32511735

Reduction in Retinal Thickness Fluctuations After Treatment With Fluocinolone Acetonide Implant for DME: A Post-Hoc Analysis of the USER Study.

Christopher D Riemann, Alexander M Eaton, Antonio Cutino.   

Abstract

BACKGROUND AND
OBJECTIVE: Assess fluocinolone acetonide implant (FAc) effects on diabetic macular edema (DME) retinal thickness fluctuations. PATIENTS AND METHODS: A post-hoc chart review of the real-world USER study analyzed patients receiving 0.2 μg/day FAc implant. The percentage of eyes with central subfield thickness (CST) of 300 µm or less were compared pre- and post-FAc implant; mean retinal thickness amplitude (RTA), retinal thickness standard deviation (RTSD), and two case studies were analyzed.
RESULTS: One hundred thirty patients (mean age: 69.6 years) presented; CST was available for 120 of 160 treated eyes. Mean RTA decreased significantly post-FAc implant (P < .001) regardless of baseline visual acuity (VA). Correlations with last-observed VA (R2) were: RTA, 0.1197; retinal thickness standard deviation (RTSD), 0.1526; and area under the CST-time curve (AUC CST), 0.0981. After FAc implant, the percentage of eyes with CST of 300 μm or less was significantly greater versus baseline (P < .05).
CONCLUSIONS: Retinal thickness fluctuations significantly declined after FAc and correlated with improvement in VA. Both RTSD and RTA measures correlated more closely to last observed VA than AUC CST itself. [Ophthalmic Surg Lasers Imaging Retina. 2020;51:298-306.].
© 2020 Riemann, Eaton, Cutino.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32511735     DOI: 10.3928/23258160-20200501-09

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging Retina        ISSN: 2325-8160            Impact factor:   1.300


  2 in total

1.  Biomarkers to Predict the Success of Treatment with the Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Uveitic Macular Edema.

Authors:  Lucy Joanne Kessler; Grzegorz Łabuz; Gerd U Auffarth; Ramin Khoramnia
Journal:  Pharmaceutics       Date:  2022-03-22       Impact factor: 6.525

2.  LONG-TERM EFFICACY OF FLUOCINOLONE IN EYES WITH IRIS-LENS DIAPHRAGM DISRUPTION AND PCME WITH MEDICATION FIXED IN THE SCLERA (MEFISTO).

Authors:  Tina R Herold; Efstathios Vounotrypidis; Raffael Liegl; Susanna F Koenig; Siegfried G Priglinger; Armin Wolf
Journal:  Retina       Date:  2022-03-15       Impact factor: 3.975

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.